Is JEOL profitable in 2026?

Yes. For FY ended March 31, 2026, JEOL's net sales fell 8.8% YoY to ¥179.35 billion, but profit attributable to owners of parent rose 18.2% YoY to a record ¥22.1 billion, with ROE at 15.7%, per its FY2026 financial results.

Could AI replace JEOL's electron microscopes?

No. AI tools like AlphaFold and cryo-EM reconstruction pipelines run on top of JEOL's physical hardware, aiding data analysis, not replacing the electron optics, cryogenics and vacuum systems that make up JEOL's core capital-equipment business, per an October 2025 review.

Is JEOL a safe company to join?

JEOL is a 77-year-old profitable Tokyo Stock Exchange listed manufacturer (ticker 6951) with consolidated headcount of 3,731 as of March 31, 2026, up 3.52% YoY, and no reported layoffs, suggesting stable if not fast-growing employment.

Who is JEOL's biggest competitor?

Thermo Fisher Scientific, roughly 100 times JEOL's revenue via its Titan Krios cryo-EM line, is the largest adjacent incumbent; JEOL also competes with Danaher, ZEISS, Bruker, Rigaku and Hitachi High-Tech, and trails IMS Nanofabrication and NuFlare in multi-beam mask writers as of June 2026.

JEOL is a public company listed on the Tokyo Stock Exchange (ticker 6951) since 1966, with no controlling parent; major institutional holders as of March 5, 2026 include Japan's Government Pension Investment Fund (about 6.99%), Nomura Asset Management, and Norges Bank Investment Management.

Is JEOL's revenue growing or shrinking?

Shrinking. After FY2025 net sales grew 12.83% to ¥196.70 billion, FY2026 (ended March 31, 2026) sales fell 8.8% to ¥179.35 billion, and management's own guidance forecasts H1 FY2027 sales down 23.2% YoY to ¥63.0 billion.

Biotech tools companies · Japan

JEOL Ltd.

jeol.com ↗

JEOL makes electron microscopes and analytical instruments for labs and chip fabs.

Defensible for now

Assessed 24 July 2026 · Evidence as of 24 July 2026

Real protection, with named pressure against it.

On the recordSince 24 July 2026 · Checkable from August 14, 2026 · Every call on the record Checkpoint: Q1 FY2027 earnings, testing whether the guided 23.2% H1 sales drop actually happens

The call

JEOL is shrinking through a semiconductor and research capex downturn while staying profitable, sitting well behind Thermo Fisher in scale but still holding specialist ground in electron microscopy.

JEOL is a 77-year-old Japanese company that builds specialized microscopes and scientific instruments used in research labs and semiconductor factories. The company is hard to replace because it has decades of know-how in electron optics and vacuum technology, and many labs already own its equipment, but it is much smaller than competitors like Thermo Fisher (which is about 100 times bigger) and does not lead in every product it makes, including multi-beam mask writers where smaller rivals like IMS Nanofabrication are stronger. The company is currently shrinking, with sales expected to fall 23 percent in the first half of 2027, so the real question is whether JEOL can hold its ground while waiting for the semiconductor market to recover or whether it will lose share to better-funded competitors who can invest more in new technology.

Why

AI pressure: None apparent. AI mostly adds demand: automated image analysis and AI-driven materials research need more of JEOL's microscopes, not fewer. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific. Thermo Fisher's Titan Krios cryo-EM line competes directly and Thermo Fisher's revenue is roughly 100 times JEOL's. Could a giant copy it? Probably.

What protects it. Decades of tacit know-how in electron optics, vacuum and cryogenics, plus installed labs that rebuy service and upgrades from JEOL rather than switch.

What would change this call

JEOL's Q1 FY2027 earnings on August 14, 2026 show sales decline near or beyond the guided 23.2% H1 drop. Would indicate the downturn is structural, not a short cyclical dip.
Major cryo-EM lab or pharma account chooses Thermo Fisher's Titan Krios over a JEOL system in a publicized tender. Would show JEOL losing flagship cryo-EM placements to the dominant rival.
New US or Japan export-control rule specifically restricts JEOL electron-optics or mask-writer exports to China. Would show regulatory risk cutting off a major JEOL market rather than just cyclical softness.

Key numbers

FY2026 net sales fell 8.8% to Y179.35 billion (2026-03-31)
FY2027 H1 sales guided down 23.2% YoY to Y63.0 billion (2026-05-14)
FY2026 profit still rose 18.2% YoY to a record Y22.1 billion (2026-03-31)

Named risks

FY2027 H1 revenue guided down 23.2% YoY to ¥63.0 billion, deepening the cyclical downturn. Severity: high
Sub-scale multi-beam mask writer position behind IMS Nanofabrication and NuFlare with slow demand recovery. Severity: high
Vast scale gap versus Thermo Fisher Scientific and Danaher in cryo-EM and analytical instruments. Severity: medium
Exposure to US-China semiconductor export control turbulence affecting fab capex cycles. Severity: medium
Yen appreciation reduced overseas sales ratio from 71.2% to 67.2% in FY2026. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	contesting	Roughly 100x JEOL revenue via Titan Krios cryo-EM line; both compete directly in cryo-EM as of 2026
IMS Nanofabrication and NuFlare	losing to	Lead multi-beam mask writer segment; JEOL management flagged slow demand recovery, 2026-06-29
Danaher Corp	contesting	About 58,000 employees vs JEOL's 3,731, per GlobalData profile, 2025-05-09
ZEISS, Bruker, Rigaku, Hitachi High-Tech	contesting	Named as direct precision-instrument competitors, per Investing.com, 2026-05-29

Questions people ask

Is JEOL profitable in 2026?: Yes. For FY ended March 31, 2026, JEOL's net sales fell 8.8% YoY to ¥179.35 billion, but profit attributable to owners of parent rose 18.2% YoY to a record ¥22.1 billion, with ROE at 15.7%, per its FY2026 financial results.
Could AI replace JEOL's electron microscopes?: No. AI tools like AlphaFold and cryo-EM reconstruction pipelines run on top of JEOL's physical hardware, aiding data analysis, not replacing the electron optics, cryogenics and vacuum systems that make up JEOL's core capital-equipment business, per an October 2025 review.
Is JEOL a safe company to join?: JEOL is a 77-year-old profitable Tokyo Stock Exchange listed manufacturer (ticker 6951) with consolidated headcount of 3,731 as of March 31, 2026, up 3.52% YoY, and no reported layoffs, suggesting stable if not fast-growing employment.
Who is JEOL's biggest competitor?: Thermo Fisher Scientific, roughly 100 times JEOL's revenue via its Titan Krios cryo-EM line, is the largest adjacent incumbent; JEOL also competes with Danaher, ZEISS, Bruker, Rigaku and Hitachi High-Tech, and trails IMS Nanofabrication and NuFlare in multi-beam mask writers as of June 2026.
Who owns JEOL Ltd?: JEOL is a public company listed on the Tokyo Stock Exchange (ticker 6951) since 1966, with no controlling parent; major institutional holders as of March 5, 2026 include Japan's Government Pension Investment Fund (about 6.99%), Nomura Asset Management, and Norges Bank Investment Management.
Is JEOL's revenue growing or shrinking?: Shrinking. After FY2025 net sales grew 12.83% to ¥196.70 billion, FY2026 (ended March 31, 2026) sales fell 8.8% to ¥179.35 billion, and management's own guidance forecasts H1 FY2027 sales down 23.2% YoY to ¥63.0 billion.

Timeline

2026-07-24Market capitalization approximately ¥400.8 billion, per gurufocus.com
2026-07-08JEOL stock drops 7.23% in a single day amid 52-week range ¥3,810 to ¥8,784
2026-06-29FY2026 results briefing; management flags slow recovery in multi-beam mask writer demand
2026-05-29Stock rallies on roughly 84% EPS beat; Jefferies raises price target to ¥9,000, buy rating
2026-05-25Sales begin for LazEdge, a laser-equipped SEM system with Hamamatsu Photonics
2026-05-14JEOL issues FY2027 H1 guidance: net sales forecast ¥63.0 billion, down 23.2% YoY
2026-04-01Medical Equipment business divested to Sysmex Corporation, effective this date
2026-03-31FY2026 closes: net sales ¥179.35 billion (-8.8% YoY), record profit of ¥22.1 billion (+18.2%)
2025-12-31Nine-month net sales down 4.8% YoY to ¥129.8 billion, operating profit down 18.6%
2025-03-31FY2025 closes: net sales ¥196.70 billion, up 12.83% YoY on record equipment demand

Revision history

24 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

DiaSorin S.p.A.Spectris plc Tecan Group